Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Impact of obsessive-compulsive disorder on the antimanic response to olanzapine therapy in youth with bipolar disorder.

Joshi G, Mick E, Wozniak J, Geller D, Park J, Strauss S, Biederman J.

Bipolar Disord. 2010 Mar;12(2):196-204. doi: 10.1111/j.1399-5618.2010.00789.x.

PMID:
20402712
2.

Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S.

J Clin Psychiatry. 2004 Apr;65(4):565-8.

PMID:
15119922
3.

Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?

Geller DA, Biederman J, Stewart SE, Mullin B, Farrell C, Wagner KD, Emslie G, Carpenter D.

J Child Adolesc Psychopharmacol. 2003;13 Suppl 1:S19-29.

PMID:
12880497
4.

Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.

Keck PE Jr, Corya SA, Altshuler LL, Ketter TA, McElroy SL, Case M, Briggs SD, Tohen M.

J Clin Psychiatry. 2005 May;66(5):611-6.

PMID:
15889948
5.

Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.

Bogetto F, Bellino S, Vaschetto P, Ziero S.

Psychiatry Res. 2000 Oct 30;96(2):91-8.

PMID:
11063782
6.

Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania.

Berk M, Ng F, Wang WV, Tohen M, Lubman DI, Vieta E, Dodd S.

J Affect Disord. 2008 Sep;110(1-2):126-34. doi: 10.1016/j.jad.2008.01.018. Epub 2008 Feb 15.

PMID:
18280579
7.

Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder.

Joshi G, Biederman J, Wozniak J, Doyle R, Hammerness P, Galdo M, Sullivan N, Williams C, Brethel K, Woodworth KY, Mick E.

CNS Neurosci Ther. 2012 Jan;18(1):28-33. doi: 10.1111/j.1755-5949.2010.00219.x. Epub 2010 Nov 29.

PMID:
21114638
8.

Acute phase results from STORM, a multicountry observational study of bipolar disorder treatment and outcomes.

Treuer T, Oruc L, Loza N, El Saidi MA, Kovacs Z, Akkaya C, Gülseren S, Saylan M, Colman SA, Harrison GA.

Psychiatr Danub. 2007 Dec;19(4):282-95.

PMID:
18000479
9.

Clinical outcome in patients with bipolar I disorder, obsessive compulsive disorder or both.

Centorrino F, Hennen J, Mallya G, Egli S, Clark T, Baldessarini RJ.

Hum Psychopharmacol. 2006 Apr;21(3):189-93.

PMID:
16625524
10.

Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study.

Marazziti D, Pfanner C, Dell'Osso B, Ciapparelli A, Presta S, Corretti G, Di Nasso E, Mungai F, Dell'Osso L.

J Psychopharmacol. 2005 Jul;19(4):392-4.

PMID:
15982994
11.

Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder.

Husted DS, Shapira NA, Murphy TK, Mann GD, Ward HE, Goodman WK.

J Psychiatr Res. 2007 Apr-Jun;41(3-4):332-7. Epub 2006 Jul 24.

PMID:
16860338
12.

Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.

Koran LM, Ringold AL, Elliott MA.

J Clin Psychiatry. 2000 Jul;61(7):514-7.

PMID:
10937610
13.

Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.

Niufan G, Tohen M, Qiuqing A, Fude Y, Pope E, McElroy H, Ming L, Gaohua W, Xinbao Z, Huichun L, Liang S.

J Affect Disord. 2008 Jan;105(1-3):101-8. Epub 2007 May 24.

PMID:
17531327
14.

Clinical predictors of drug nonresponse in obsessive-compulsive disorder.

Shetti CN, Reddy YC, Kandavel T, Kashyap K, Singisetti S, Hiremath AS, Siddequehusen MU, Raghunandanan S.

J Clin Psychiatry. 2005 Dec;66(12):1517-23.

PMID:
16401151
15.

The antidepressant effects of risperidone and olanzapine in bipolar disorder.

McIntyre RS, Mancini DA, Srinivasan J, McCann S, Konarski JZ, Kennedy SH.

Can J Clin Pharmacol. 2004 Fall;11(2):e218-26. Epub 2004 Oct 4.

PMID:
15520475
16.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
17.

Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children.

Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, Wozniak J.

Biol Psychiatry. 2005 Oct 1;58(7):589-94.

PMID:
16239162
18.

The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder.

Shavitt RG, Valério C, Fossaluza V, da Silva EM, Cordeiro Q, Diniz JB, Belotto-Silva C, Cordioli AV, Mari J, Miguel EC.

Eur Arch Psychiatry Clin Neurosci. 2010 Mar;260(2):91-9. doi: 10.1007/s00406-009-0015-3.

PMID:
20077119
19.

Clinical characteristics of comorbid obsessive-compulsive disorder and bipolar disorder in children and adolescents.

Joshi G, Wozniak J, Petty C, Vivas F, Yorks D, Biederman J, Geller D.

Bipolar Disord. 2010 Mar;12(2):185-95. doi: 10.1111/j.1399-5618.2010.00795.x.

20.

The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.

Lee JH, Dunner DL.

Depress Anxiety. 2008;25(2):91-7.

PMID:
17311265
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk